Vildagliptin

Generic Name: Vildagliptin

Brand Names: Galvus, Jalra, Xiliarx

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₅N_₃O_₂

CAS Number: 274901-16-5

Unique Ingredient Identifier: I6B4B2U96P

Background: Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...

Indication: Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis

Target Recruit Count: 478

Registration Number: NCT00138619

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 530

Registration Number: NCT00138567

Locations: 🇩🇪
Novartis Investigative site, Investigative Centers, Germany
🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 179

Registration Number: NCT00138606

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪
Novartis Investigative Site, Investigative Centers, Germany

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis

Target Recruit Count: 180

Registration Number: NCT00138593

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis

Target Recruit Count: 440

Registration Number: NCT00138541

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: vildagliptin
Drug: pioglitazone

First Posted Date: 2005-08-30

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 318

Registration Number: NCT00138554

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-08-30

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis

Target Recruit Count: 418

Registration Number: NCT00138515

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-07-18

Last Posted Date: 2017-05-18

Lead Sponsor: Novartis

Target Recruit Count: 288

Registration Number: NCT00120536

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-05-05

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 594

Registration Number: NCT00110240

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: vildagliptin
Drug: glimepiride
Drug: Metformin
Drug: Vildagliptin matching placebo
Drug: Glimepiride matching placebo

First Posted Date: 2005-03-23

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3118

Registration Number: NCT00106340

Locations: 🇩🇪
Investigative Centers, Nurnberg, Germany
🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy